Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with a prevalence of 5% to 15% in premenopausal women. Patients with PCOS presents as abnormal menstruation, ovulation disorders and/or hyperandrogenemia, and often accompanied by insulin resistance and other metabolic abnormalities. Abdominal fat accumulation, overweightness and obesity are frequently present in patients with PCOS . Visceral adipose tissue (VAT) plays an important role in the pathogenesis of PCOS.Therefore,this study aim to investigate the changes of body fat distribution in obese women with PCOS after laparoscopic sleeve gastrectomy (LSG), and to explore the factors that may predict the changes in body fat distribution in PCOS patients after LSG.
This study consecutively enrolled 153 patients with obesity aged 18-45 years (83 with PCOS and 70 control patients) who underwent LSG from May 2013 to September 2020 at the Department of Endocrinology, Shanghai Tenth People's Hospital, with a 12-month follow-up. Dual-energy X-ray absorptiometry (DEXA) was used to assess body fat distribution.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PCOS group | Experimental | obese female patients with Polycystic ovary syndrome. All participants underwent laparoscopic sleeve gastrectomy (LSG) |
|
| control group | Active Comparator | obese female patients without Polycystic ovary syndrome. All participants underwent laparoscopic sleeve gastrectomy (LSG) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| laparoscopic sleeve gastrectomy (LSG) | Procedure | Multiple studies have indicated that laparoscopic sleeve gastrectomy (LSG) was superior to nonsurgical approaches for the treatment of obese PCOS patients over both the short and long term |
| Measure | Description | Time Frame |
|---|---|---|
| VAT mass | visceral adipose tissue (VAT) mass | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| BMI | Body mass index (BMI) was calculated as follows: BMI = (body weight [kg])/(height [m2]) | 12 months |
| FBG | fasting blood-glucose in mmol/L |
Not provided
Inclusion Criteria:
Exclusion Criteria:
6) concurrent participation in other clinical trials; 7) sever endocrine and hereditary diseases; 8) mental illnesses that rendered them unable to provide informed consent; 9) patients declining to undergo complete study testing.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Shen Qu, Dr | Shang hai Tenth People's Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Endocrinology, Shanghai Tenth People's Hospital | Shanghai | Shanghai Municipality | 200070 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34152560 | Background | Cai M, Gao J, Du L, Cheng X, Zhou D, Zhu J, Qu S, Zhang M. The Changes in Body Composition in Obese Patients with Polycystic Ovary Syndrome after Laparoscopic Sleeve Gastrectomy:a 12-Month Follow-up. Obes Surg. 2021 Sep;31(9):4055-4063. doi: 10.1007/s11695-021-05496-6. |
| Label | URL |
|---|---|
| The Changes in Body Composition in Obese Patients with Polycystic Ovary Syndrome after Laparoscopic Sleeve Gastrectomy:a 12-Month Follow-up | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011085 | Polycystic Ovary Syndrome |
| ID | Term |
|---|---|
| D010048 | Ovarian Cysts |
| D003560 | Cysts |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
| D000291 |
Not provided
Not provided
Parallel Assignment
Not provided
Not provided
Not provided
Not provided
| 12 months |
| PBG | postprandial blood-glucose in mmol/L | Baseline and 12 months |
| FINS | fasting serum insulin in mU/L | Baseline and 12 months |
| PINS | postprandial insulin in mU/L | Baseline and 12 months |
| ALT | alanine aminotransferase in U/L | Baseline and 12 months |
| AST | aspartate aminotransferase in U/L) | Baseline and 12 months |
| UA | Uric acid in umol/L | Baseline and 12 months |
| CR | Creatinine in umol/L | Baseline and 12 months |
| LDL-c | low-density lipoprotein cholesterol in mmol/L | Baseline and 12 months |
| HDL-c | high-density lipoprotein cholesterol in mmol/L | Baseline and 12 months |
| TC | Total Cholesterol in mmol/L | Baseline and 12 months |
| TG | Triglyceride in mmol/L | Baseline and 12 months |
| WHR | waist-to-hip ratio (WHR) were calculated as follows: WHR = (waist circumference [cm]/(hip circumference [cm]). | Baseline and 12 months |
| HC | Hip circumference | Baseline and 12 months |
| Ferriman-Gallwey score | Ferriman-Gallwey score | Baseline and 12 months |
| Menstrual Cycles | The number of menstrual cycles per year was defined as the number of menstruations during the last 12 months. | Baseline and 12 months |
| HOMA-IR | homeostatic model assessment insulin resistance index | Baseline and 12 months |
| TT | total testosterone in nmol/L | Baseline and 12 months |
| FT | free testosterone (nmol/L) | Baseline and 12 months |
| DHEAS | Dehydroepiandrosterone Sulfate (ug/dl) | Baseline and 12 months |
| SHBG | sex hormone-binding globulin in nmol/L | Baseline and 12 months |
| FSH | follicle-stimulating hormone in IU/L | Baseline and 12 months |
| LH | luteinizing hormone in IU/L | Baseline and 12 months |
| WC | waist circumference, | Baseline and 12 months |
| Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |